Australia markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
142.84-1.69 (-1.17%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close144.53
Open143.58
Bid0.00 x 900
Ask0.00 x 900
Day's range140.46 - 143.58
52-week range72.05 - 175.00
Volume560,175
Avg. volume744,812
Market cap11.175B
Beta (5Y monthly)1.84
PE ratio (TTM)N/A
EPS (TTM)-7.00
Earnings date05 Nov 2020 - 09 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est192.50
  • GlobeNewswire

    Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

    CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 21 recipients of Route 79, The Duchenne Scholarship Program. This is the third year of the scholarship program, which was created to recognize exceptional individuals with Duchenne muscular dystrophy as they pursue their post-secondary education. Recipients were chosen by an independent selection committee composed of Duchenne community members, who consider each applicant’s community involvement and a personal essay. Each student will receive a scholarship of up to $5,000. “It is our great privilege to announce and congratulate the 2020 recipients of Route 79, The Duchenne Scholarship Program. With each new class of applicants, we are reminded of the varied interests, skills, and goals of these bright young people. Their perseverance and resiliency, particularly in the face of the challenges and uncertainties brought on by COVID, set a powerful example for others living with Duchenne,” said Diane Berry, Sarepta’s Senior Vice President of Global Health Policy, Government and Patient Affairs. “It is an honor to play a role in supporting their journey in higher education and we wish them great success. Additionally, I want to extend gratitude and appreciation to the selection committee for generously giving of their time to review the applications and essays.”2020 Named Recipients - Route 79, The Duchenne Scholarship ProgramPraise Akintola, Farmingdale State CollegePorter Aydelotte, Saddleback CollegeDonovan Carlson, University of Illinois at Urbana-ChampaignTyler Cooley, Arizona State UniversityLucas Currier, Great Bay Community CollegeBenjamin Dupree, The University of Texas at ArlingtonCole Dutton, West Texas A&M UniversityAiden Fecteau, Eastern Connecticut State UniversityYuvaraj Gambhir, University of PennsylvaniaJustin Gibbons, Saint Bonaventure UniversityWilliam Hancock, Merrimack CollegeJoshua Jurack, James Madison UniversityBrian Le, Stanford UniversityBrian Madura, New Jersey Institute of TechnologyAlice McConnell, University of IdahoNicholas O'Neill, Morrisville State CollegeSpencer Poole, Saint Joseph’s College - Suffolk CampusJordan Reidenberg, University of DelawareNathan Rothe, Texas Christian UniversityChristian Tumminello, Pennsylvania College of TechnologyJack Willis, Syracuse UniversityScholarship recipients are chosen by an independent committee of Duchenne community members based on each applicant’s essay and demonstrated level of community involvement. Submissions are de-identified for the voting panel with no indication of whether the candidate has received, or plans to receive, a Sarepta therapy.About Route 79, The Duchenne Scholarship ProgramRoute 79, The Duchenne Scholarship Program is designed to help students diagnosed with Duchenne muscular dystrophy (Duchenne) pursue their post-high school educational goals. There are 79 exons in the dystrophin gene impacted by Duchenne, and the route traveled by every person with Duchenne is distinct. Sarepta’s goal through this program is to acknowledge and support individuals with Duchenne who are mapping out their future via educational pursuits. Additional information is available at https://www.sarepta.com/route79. About Sarepta Therapeutics At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.Source: Sarepta Therapeutics, Inc.Sarepta Therapeutics, Inc.Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.com Media: Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com

  • GlobeNewswire

    Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society

    \-- Webcast conference call to be held on Monday, Sept. 28, 2020 at 8:30 a.m. Eastern Time --\-- Additional poster presentations at WMS will highlight data from Sarepta’s RNA and gene therapy programs --CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that new data from its most advanced gene therapy programs will be presented at the WMS25 Virtual Congress, the 25th International Annual Congress of the World Muscle Society, being held Sept. 28 – Oct. 2.Sarepta will host a webcast and conference call on Monday, Sept. 28, 2020 at 8:30 a.m. ET, to discuss the results, which include two-year functional data from Study 101 of SRP-9001 for Duchenne muscular dystrophy and 18-month functional results from Cohort 1 in the study of SRP-9003 for Limb-girdle muscular dystrophy Type 2E.This will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the call for one year. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 6793650. Please specify to the operator that you would like to join the "Long-term Functional Data from Sarepta’s Gene Therapy Programs” call.In total, Sarepta will present 16 abstracts at this year’s meeting. All posters will be available on-demand throughout the Congress beginning on Monday, Sept. 28 at 7:00 a.m. EST. The full WMS25 Virtual Congress program is available here: https://www.wms2020.com/programme/.Gene Therapy: TITLEPROGRAMPOSTER Treatment of Aged Mice and Long-term Durability of AAV-Mediated Gene Therapy in Two Mouse Models of Limb Girdle Muscular DystrophySRP-9003, SRP-9004 P.137 Expression-Functional Correlation and Validation of a Surrogate Marker for DAPC Restoration in LGMD2E Mouse ModelSRP-9003P.139 Systemic Gene Transfer with rAAVrh74.MHCK7.SGCB Increased β-sarcoglycan Expression in Patients with Limb Girdle Muscular Dystrophy Type 2ESRP-9003P.140 Evaluation of the Lipid-Binding and Stability Properties of Recombinant Dystrophin Spectrin-Like Repeat ConstructsSRP-9001P.206 Systemic Gene Transfer with rAAVrh74.MHCK7.micro-dystrophin in Patients with Duchenne Muscular DystrophySRP-9001P.280 Systemic Dose-Finding Study with AAV-Mediated γ-Sarcoglycan Gene Therapy for Treatment of Muscle Deficits in LGMD2C MiceSRP-9005P.138 RNA Platform: TITLEPROGRAMPOSTER Long-term Safety and Efficacy of Golodirsen in Male Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 SkippingGolodirsenP.283 Casimersen Treatment in Eligible Patients with Duchenne Muscular Dystrophy: Safety, Tolerability, and Pharmacokinetics Over 144 Weeks of TreatmentCasimersenP.288 Open-Label Evaluation of Eteplirsen in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI TrialEteplirsenP.289 Delay in Duchenne Muscular Dystrophy Progression with Eteplirsen: Attenuation of Pulmonary Decline and Projected Freedom from Continuous VentilationEteplirsenP.290 Real-world Evidence of Eteplirsen Treatment Effects on Duchenne Muscular Dystrophy Related Health Outcomes Using Claims Data in the United StatesEteplirsenP.291 Natural history and other presentations: TITLEPOSTER Development of Cardiomyopathy, Respiratory Insufficiency and Loss of Ambulation in Becker Muscular Dystrophy: A Systematic Literature ReviewP.41 Disease Attributes Most Important from a Societal Perspective: A Case Study Involving Duchenne Muscular DystrophyP.56 Identification of Disease Progression Stages in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Data in the United StatesP.119 The Age at Loss of Ambulation Among Patients with Limb-Girdle Muscular Dystrophy (LGMD) Subtype 2: A Systematic ReviewP.142 Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients with Duchenne Muscular DystrophyP.345 Presentations will be archived under the events and presentations section of the Sarepta Therapeutics website at www.sarepta.com for one year following their presentation at WMS25. About Sarepta Therapeutics At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc.Sarepta Therapeutics, Inc.Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.comMedia: Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com

  • GlobeNewswire

    Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

    CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has completed a Type C ‘written response only’ meeting with the Office of Tissues and Advanced Therapies (OTAT), part of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), to obtain OTAT’s concurrence on the commencement of its next clinical trial for SRP-9001 using commercial process material. SRP-9001 (AAVrh74.MHCK7.micro-dystrophin) is Sarepta’s investigational gene transfer therapy for the treatment of Duchenne muscular dystrophy. Among other items, OTAT has requested that Sarepta utilize an additional potency assay for release of SRP-9001 commercial process material prior to dosing in a clinical study. Sarepta has several existing assays and data that it believes could be employed in response to OTAT’s request. However, additional dialogue with the Agency is required to determine the acceptability of the potency assay approach.“We look forward to working with OTAT to potentially satisfy their requests and to obtain clarity on the timing of the commencement of our commercial supply study. We will provide further updates as we are able,” said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. “Every day, thousands of children degenerate from the irreversible damage caused by Duchenne muscular dystrophy. It is for that reason that we will work relentlessly with the Division to satisfy any requests of OTAT and continue the advancement of a potentially transformative therapy for these patients.”  About SRP-9001 (AAVrh74.MHCK7.micro-dystrophin) SRP-9001 is an investigational gene transfer therapy intended to deliver the micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. Sarepta is responsible for global development and manufacturing for SRP-9001 and plans to commercialize SRP-9001 in the United States. In December 2019, the Company announced a licensing agreement granting Roche the exclusive right to launch and commercialize SRP-9001 outside the United States. Sarepta has exclusive rights to the micro-dystrophin gene therapy program initially developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital.About Sarepta Therapeutics At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.  For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.Sarepta Forward-Looking Statements This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding Sarepta’s belief that its existing assays and data could be employed in response to OTAT’s request; the acceptability of Sarepta’s potency assay approach by the FDA; our plan to work with OTAT to potentially satisfy their requests and to obtain clarity on the timing of the commencement of our commercial supply study; and the potential of SRP-9001 to be a transformative therapy for DMD patients. These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: delays in the commencement of Sarepta’s next clinical study for SRP-9001 could delay, prevent or limit our ability to gain regulatory approval for SRP-9001; any inability to complete successfully clinical development could result in additional costs to Sarepta or impair Sarepta’s ability to generate revenues from product sales, regulatory and commercialization milestones and royalties; SRP-9001 may not result in a viable treatment suitable for commercialization due to a variety of reasons, including the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; Sarepta may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its product candidates to market, due to a variety of reasons, many of which may be outside of Sarepta’s control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta’s product candidates and the COVID-19 pandemic; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review.Any of the foregoing risks could materially and adversely affect Sarepta’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc.Sarepta Therapeutics, Inc.Investors: Ian Estepan, 617-274-4052 iestepan@sarepta.com Media: Tracy Sorrentino, 617-301-8566 tsorrentino@sarepta.com